Quick Answer
BRAINSTORM CELL THERAPEUTICS INC. reported Net Income of -$10.31 million for fiscal year 2025.
BRAINSTORM CELL THERAPEUTICS INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$10.31M +11.3% |
-$11.62M +32.4% |
-$17.19M +29.2% |
-$24.28M +0.7% |
-$24.46M +23.1% |
-$31.81M -36.8% |
| Diluted EPS | -$1.11 +51.9% |
-$2.31 +61.5% |
-$6.00 -809.1% |
-$0.66 +2.9% |
-$0.68 +36.4% |
-$1.07 |
| Total Assets | $1.02M -44.2% |
$1.83M -56.5% |
$4.21M -50.2% |
$8.45M -71.1% |
$29.28M -42.9% |
$51.26M +684.5% |
| Cash and Equivalents | $29.0K -84.5% |
$187.0K -85.6% |
$1.30M +68.4% |
$772.0K -95.9% |
$18.86M -50.2% |
$37.83M +6957.6% |
| Stockholders Equity | -$9.98M -28.6% |
-$7.76M -59.8% |
-$4.86M -61.1% |
-$3.02M -115.6% |
$19.34M -45.5% |
$35.46M +390.1% |
| R&D Expense | $4.17M -10.2% |
$4.65M -56.7% |
$10.75M -23.0% |
$13.96M -8.4% |
$15.23M -31.8% |
$22.33M +29.8% |
| Operating Income | -$9.95M +14.9% |
-$11.69M +45.5% |
-$21.44M +13.6% |
-$24.82M -1.2% |
-$24.54M +22.6% |
-$31.68M -37.8% |
| Shares Outstanding | 11.03M +79.7% |
6.14M +52.3% |
4.03M -89.0% |
36.69M +0.8% |
36.40M +3.5% |
35.16M +51.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$2.11M | +22.2% | +27.5% |
| Diluted EPS | September 30, 2025 | -$0.19 | +62.7% | +44.1% |
| Total Assets | September 30, 2025 | $1.38M | -31.9% | -46.2% |
| Cash and Equivalents | September 30, 2025 | $5.0K | -97.0% | -99.4% |
| Stockholders Equity | September 30, 2025 | -$7.69M | -27.0% | -27.0% |
| R&D Expense | September 30, 2025 | $899.0K | -14.0% | -19.7% |
| Operating Income | September 30, 2025 | -$2.05M | +32.8% | +20.4% |
| Shares Outstanding | September 30, 2025 | 11.03M | +107.8% | +9.0% |
- BRAINSTORM CELL THERAPEUTICS INC. reported Net Income of -$10.31 million for fiscal year 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed an increase of +11.3% in Net Income compared to the prior fiscal year.
- BRAINSTORM CELL THERAPEUTICS INC. reported Diluted EPS of $1.11 per share (loss) for fiscal year 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed an increase of +51.9% in Diluted EPS compared to the prior fiscal year.
- BRAINSTORM CELL THERAPEUTICS INC. reported Total Assets of $1.02 million for fiscal year 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed a decrease of -44.2% in Total Assets compared to the prior fiscal year.
- BRAINSTORM CELL THERAPEUTICS INC. reported Cash and Equivalents of $29.0 thousand for fiscal year 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed a decrease of -84.5% in Cash and Equivalents compared to the prior fiscal year.
- BRAINSTORM CELL THERAPEUTICS INC. reported Stockholders Equity of -$9.98 million for fiscal year 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed a decrease of -28.6% in Stockholders Equity compared to the prior fiscal year.
- BRAINSTORM CELL THERAPEUTICS INC. reported R&D Expense of $4.17 million for fiscal year 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed a decrease of -10.2% in R&D Expense compared to the prior fiscal year.
- BRAINSTORM CELL THERAPEUTICS INC. reported Operating Income of -$9.95 million for fiscal year 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed an increase of +14.9% in Operating Income compared to the prior fiscal year.
- BRAINSTORM CELL THERAPEUTICS INC. reported Shares Outstanding of 11.03 million shares for fiscal year 2025.
- BRAINSTORM CELL THERAPEUTICS INC. showed an increase of +79.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: